The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).

Kelly S. Oliner

Employment or Leadership Position - Amgen

Stock Ownership - Amgen

Jean-Yves Douillard

Consultant or Advisory Role - Amgen

Honoraria - Amgen

Salvatore Siena

Consultant or Advisory Role - Amgen; Bayer; Celgene; Genomic Health; Roche; Sanofi

Josep Tabernero

Consultant or Advisory Role - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; ImClone Systems; Lilly; Merck KGaA

Honoraria - Amgen; Merck KGaA; Novartis; Roche; Sanofi

Ronald L. Burkes

Consultant or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Lilly; Sanofi

Honoraria - Amgen; Biogen Idec; Boehringer Ingelheim; Lilly; Roche; Sanofi

Mario Edmundo Barugel

Consultant or Advisory Role - Roche

Honoraria - Amgen; Roche

Yves Humblet

Consultant or Advisory Role - Amgen

Honoraria - Amgen

Research Funding - Amgen

Gyorgy Bodoky

Consultant or Advisory Role - Amgen

David Cunningham

Employment or Leadership Position - Royal Marsden NHS Foundation Trust

Research Funding - Amgen; Celgene; Merck Serono; Novartis; Roche; Sanofi

Jacek Jassem